Literature DB >> 20621254

The role of aldosteronism in causing obesity-related cardiovascular risk.

David A Calhoun1, Kumar Sharma.   

Abstract

A large body of evidence strongly links aldosterone to development and progression of cardiovascular disease, including vascular stiffness, left ventricular hypertrophy, congestive heart failure, chronic kidney disease, and, especially, hypertension. Emerging data suggest that adipocytes may serve as a source of aldosterone, either directly or indirectly, through the release of aldosterone-stimulating factors. If adipocytes are confirmed to have an important contribution to hyperaldosteronism, it would have significant clinical implications in linking aldosterone to obesity-related increases in cardiovascular risk. Such a cause-and-effect situation would then provide the opportunity to reverse that risk with preferential use of aldosterone antagonists in obese patients. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20621254      PMCID: PMC2904339          DOI: 10.1016/j.ccl.2010.04.001

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  60 in total

1.  Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.

Authors:  B J Gallay; S Ahmad; L Xu; B Toivola; R C Davidson
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

2.  Arterial pressure, left ventricular mass, and aldosterone in essential hypertension.

Authors:  A H El-Gharbawy; V S Nadig; J M Kotchen; C E Grim; K B Sagar; M Kaldunski; P Hamet; Z Pausova; D Gaudet; F Gossard; T A Kotchen
Journal:  Hypertension       Date:  2001-03       Impact factor: 10.190

3.  Insulin, renin-aldosterone system and blood pressure in obese people.

Authors:  G Andronico; S Cottone; M T Mangano; R Ferraro-Mortellaro; G Baiardi; N Grassi; L Ferrara; G Mulé; G Cerasola
Journal:  Int J Obes Relat Metab Disord       Date:  2001-02

4.  Chronic potassium depletion induces renal injury, salt sensitivity, and hypertension in young rats.

Authors:  P E Ray; S Suga; X H Liu; X Huang; R J Johnson
Journal:  Kidney Int       Date:  2001-05       Impact factor: 10.612

5.  Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.

Authors:  R Rocha; C T Stier; I Kifor; M R Ochoa-Maya; H G Rennke; G H Williams; G K Adler
Journal:  Endocrinology       Date:  2000-10       Impact factor: 4.736

6.  Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

Authors:  Myron H Weinberger; Barbara Roniker; Scott L Krause; Robert J Weiss
Journal:  Am J Hypertens       Date:  2002-08       Impact factor: 2.689

7.  Programming of hypertension: associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure.

Authors:  Rebecca M Reynolds; Brian R Walker; David I Phillips; Elaine M Dennison; Robert Fraser; Scott M Mackenzie; Eleanor Davies; John M Connell
Journal:  Hypertension       Date:  2009-04-20       Impact factor: 10.190

8.  Efficacy of spironolactone therapy in patients with true resistant hypertension.

Authors:  Fabio de Souza; Elizabeth Muxfeldt; Roberto Fiszman; Gil Salles
Journal:  Hypertension       Date:  2009-10-26       Impact factor: 10.190

9.  Familial and phenotypic associations of the aldosterone Renin ratio.

Authors:  Samantha Alvarez-Madrazo; Sandosh Padmanabhan; Bongani M Mayosi; Hugh Watkins; Peter Avery; A Michael Wallace; Robert Fraser; Eleanor Davies; Bernard Keavney; John M Connell
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

10.  Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.

Authors:  Nitin Khosla; Rigas Kalaitzidis; George L Bakris
Journal:  Am J Nephrol       Date:  2009-09-09       Impact factor: 3.754

View more
  29 in total

1.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

Review 2.  Aldosterone Production and Signaling Dysregulation in Obesity.

Authors:  Andrea Vecchiola; Carlos F Lagos; Cristian A Carvajal; Rene Baudrand; Carlos E Fardella
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

3.  New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.

Authors:  Ana Paula Davel; Iris Z Jaffe; Rita C Tostes; Frederic Jaisser; Eric J Belin de Chantemèle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-29       Impact factor: 4.733

Review 4.  Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease.

Authors:  Nicholas C Bene; Pilar Alcaide; Henry H Wortis; Iris Z Jaffe
Journal:  Steroids       Date:  2014-04-21       Impact factor: 2.668

Review 5.  Primary aldosteronism: a common cause of resistant hypertension.

Authors:  Gregory A Kline; Ally P H Prebtani; Alexander A Leung; Ernesto L Schiffrin
Journal:  CMAJ       Date:  2017-06-05       Impact factor: 8.262

6.  What Is the Role of the Adipocyte Mineralocorticoid Receptor in the Metabolic Syndrome?

Authors:  Celso E Gomez-Sanchez
Journal:  Hypertension       Date:  2015-05-11       Impact factor: 10.190

7.  Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity.

Authors:  Luminita H Pojoga; Rene Baudrand; Gail K Adler
Journal:  Eur Heart J       Date:  2013-05-10       Impact factor: 29.983

8.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

9.  Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice.

Authors:  Anne-Cécile Huby; Laszlo Otvos; Eric J Belin de Chantemèle
Journal:  Hypertension       Date:  2016-03-07       Impact factor: 10.190

Review 10.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.